[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334567-105":59,"doc-detail-334567-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncogenic-potential-of-replication-factor-c-subunit-4-correlations-with-tumor-progression-and-assessment-of-potential-inhibitors","Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors","","Replication Factor C Subunit 4 (RFC4) is an oncogene implicated in many human cancers, with limited characterization across cancer types. Bioinformatics analyses were used to evaluate RFC4 as an oncogenic driver and therapeutic target across multiple malignancies. RFC4 expression was related to tumor grade, stage, metastasis, and patient survival, alongside assessment of genetic alterations, epigenetic methylation, and effects on tumor microenvironment immune-cell infiltration. RFC4 connections with immunological checkpoints and potential pathways were explored, with results indicating upregulation and poor prognostic associations, plus identification of anti-cancer compounds that inhibit RFC4 activity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncogenic-potential-of-replication-factor-c-subunit-4-correlations-with-tumor-progression-and-assessment-of-potential-inhibitors/334567/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncogenic-potential-of-replication-factor-c-subunit-4-correlations-with-tumor-progression-and-assessment-of-potential-inhibitors/334567.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is RFC4 and why is it relevant to cancer research?","Question",{"text":112,"@type":113},"RFC4 is described as an oncogene implicated in many human cancers. The study focuses on its expression patterns and functional role across cancer types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study evaluate RFC4’s relationship with tumor progression and patient outcomes?",{"text":117,"@type":113},"The researchers examine RFC4 expression levels across tumor types and assess correlations with tumor grade, stage, metastasis, and patient survival.",{"name":119,"@type":110,"acceptedAnswer":120},"Which additional biological mechanisms and pathways are analyzed beyond expression?",{"text":121,"@type":113},"The study analyzes RFC4 genetic changes, epigenetic methylation, and impacts on tumor microenvironment immune-cell infiltration, including links to immunological checkpoints and potential carcinogenesis pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334567,1790662647,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":41,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","pharmaceuticals  \nArticle  \nOncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors  \nMuhammad Alaa Eldeen 1, *,†, Farag Mamdouh 2,†, Waleed K. Abdulsahib 3, Refaat A. Eid 4, Ahmad A. Alhanshani 5, Ayed A. Shati 5, Youssef A. Alqahtani 5, Mohammed A. Alshehri 5, Mohamed Samir A. Zaki 6, Mohamed A. Soltan 7 and Ahmed E. Noreldin 8, *  \nCitation: Alaa Eldeen, M.; Mamdouh, F.; Abdulsahib, W.K.; Eid, R.A.;  \nAlhanshani, A.A.; Shati, A.A.; Alqahtani, Y.A.; Alshehri, M.A.; Samir A. Zaki, M.; Soltan, M.A.; et al. Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors. Pharmaceuticals 2024, 17, 152. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ph17020152](10.3390/ph17020152)  \nAcademic Editor: Giorgio Cozza  \nReceived: 10 December 2023  \nRevised: 1 January 2024  \nAccepted: 11 January 2024  \nPublished: 23 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Cell Biology, Histology & Genetics Division, Zoology Department, Faculty of Science, Zagazig University, Zagazig 44519, Egypt  \n2 Biotechnology Division, Zoology Department, Faculty of Science, Benha University, Al Qalyubia Governorate, Banha 13511, Egypt; [farag199530@fsc.bu.edu.eg](farag199530@fsc.bu.edu.eg)  \n3 Pharmacology and Toxicology Department, College of Pharmacy, Al Farahidi University, Baghdad 00965, Iraq  \n4 Pathology Department, College of Medicine, King Khalid University, Abha P.O. Box 62529, Saudi Arabia; [raeid@kku.edu.sa](raeid@kku.edu.sa)  \n5 Department of Child Health, College of Medicine, King Khalid University, Abha P.O. Box 62529, Saudi Arabia; [ashati@kku.edu.sa](ashati@kku.edu.sa) (A.A.S.); [yal-qahtani@kku.edu.sa](yal-qahtani@kku.edu.sa) (Y.A.A.); [mohamed8964@hotmail.com](mohamed8964@hotmail.com) (M.A.A.)  \n6 Anatomy Department, College of Medicine, King Khalid University, Abha P.O. Box 62529, Saudi Arabia  \n7 Department of Microbiology and Immunology, Faculty of Pharmacy, Sinai University, Ismailia 41611, Egypt; [mohamed.mohamed@su.edu.eg](mohamed.mohamed@su.edu.eg)  \n8 Department of Histology and Cytology, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Egypt  \n* Correspondence: [dr.muhammadalaa@gmail.com](dr.muhammadalaa@gmail.com) (M.A.E.); [ahmed.elsayed@damanhour.edu.eg](ahmed.elsayed@damanhour.edu.eg) (A.E.N.)† These authors contributed equally to this work.  \nAbstract: Replication Factor C Subunit 4 (RFC4), an oncogene implicated in many human cancers, has yet to be extensively studied in many cancer types to determine its expression patterns and tumor tissue function. Various bioinformatics tools were used to analyze RFC4 as a potential oncogene and therapeutic target across many cancers. We first examined RFC4 expression levels in several human tumor types to determine relationships with tumor grade, stage, metastasis, and patient survival. We also examined RFC4’s genetic changes, epigenetic methylation, and effect on tumor microenvironment (TME) immune cell infiltration. We also analyzed RFC4’s connections with immunological checkpoints to identify potential molecular pathways involved in carcinogenesis. Our findings show that RFC4 is upregulated in several tumor types and associated with poor prognoses in many human cancers. This study shows that RFC4 significantly affects the tumor immunological microenvironment, specifically immune cell populations. Finally, we screened for RFC4-inhibiting pharmacological compounds with anti-cancer potential. This study fully elucidates RFC4’s carcinogenic activities, emphasizing its potential as a pro","cbCain39uMQG5kHU","https://ap.wps.com/l/cbCain39uMQG5kHU","pdf",18703345,"English","# Introduction\n## Tumorigenesis and gene dysregulation\n## Pan-cancer marker and therapeutic target discovery\n## Cancer databases and bioinformatics tools\n## Genetic mutations and immunotherapy context","[{\"question\":\"What is RFC4 and why is it relevant to cancer research?\",\"answer\":\"RFC4 is described as an oncogene implicated in many human cancers. The study focuses on its expression patterns and functional role across cancer types.\"},{\"question\":\"How does the study evaluate RFC4’s relationship with tumor progression and patient outcomes?\",\"answer\":\"The researchers examine RFC4 expression levels across tumor types and assess correlations with tumor grade, stage, metastasis, and patient survival.\"},{\"question\":\"Which additional biological mechanisms and pathways are analyzed beyond expression?\",\"answer\":\"The study analyzes RFC4 genetic changes, epigenetic methylation, and impacts on tumor microenvironment immune-cell infiltration, including links to immunological checkpoints and potential carcinogenesis pathways.\"}]","Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors | PDF",1790007250,76]